Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.38 |
| ▸ | LMNA | P02545 | 5/20 | 0.37 |
| ▸ | HTT | P42858 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MITF | O75030 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MGMT | P16455 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4297309 | 0.80 | MAPT (0.35) | MAPTLMNAHTTMITFSMN1; SMN2 | |
| SCHEMBL5145767 | 0.80 | MAPT (0.47) | MAPTLMNAHTTKDM4EMITF | |
| SCHEMBL8565117 | 0.78 | MAPT (0.39) | MAPTLMNAHTTKDM4EMITF | |
| SCHEMBL8558130 | 0.76 | NOS2 (0.44) | MAPTLMNAHTTKDM4EMITF | |
| SCHEMBL9995175 | 0.75 | HTT (0.42) | MAPTLMNAHTTKDM4EMITF | |
| SCHEMBL8598075 | 0.75 | HTT (0.42) | MAPTLMNAHTTKDM4EMITF | |
| SCHEMBL27766587 | 0.74 | HTT (0.44) | MAPTLMNAHTTKDM4EMITF | |
| SCHEMBL14764478 | 0.73 | MEN1 (0.54) | MAPTLMNAHTTKDM4EMITF | |
| SCHEMBL29871162 | 0.73 | MEN1 (0.54) | MAPTLMNAHTTKDM4EMITF | |
| SCHEMBL9987621 | 0.73 | HTT (0.40) | MAPTLMNAHTTKDM4EMITF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071592-B2 | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones | GLAXO GROUP LIMITED (GB) | 2011-12-06 | — | — | US | disclosed |
| US-20090270374-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | GLAXO GROUP LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| EP-1992628-A1 | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones | GLAXO GROUP LIMITED (GB) | 2008-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270374-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | ETFA, NQO2, GNAQ | MAPT 3830/4885LMNA 905/4885HTT 2702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.